Sutter Health investigators helped contribute to the earlier phase 2 research that established promising evidence for this personalized vaccine approach. Now, newly released results from the larger international phase 3 INTerpath-001 trial provide further evidence of its potential, showing that the personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma recurrence or death at two years compared with pembrolizumab alone.
